Skip to main content
Erschienen in: Journal of Neurology 10/2015

01.10.2015 | Original Communication

Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS)

verfasst von: Ayako Wada, Michiyuki Kawakami, Meigen Liu, Eri Otaka, Atsuko Nishimura, Fumio Liu, Tomoyoshi Otsuka

Erschienen in: Journal of Neurology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Dysphagia is one of the most critical problems in patients with progressive neuromuscular diseases. However, clinically useful and practical scales to evaluate dysphagia are limited. Therefore, the aim of this study was to develop such a scale. An 8-stage Neuromuscular Disease Swallowing Status Scale (NdSSS) was developed and tested for its inter- and intrarater reliabilities, concurrent validity, and responsiveness. The NdSSS was used to evaluate 134 patients with Duchenne muscular dystrophy (DMD) and 84 patients with amyotrophic lateral sclerosis (ALS). Inter- and intrarater reliabilities were examined with weighted kappa statistics. Concurrent validity was assessed by correlating the NdSSS with the existing scales [Functional Oral Intake Scale (FOIS), Functional Intake LEVEL Scales (FILS), and ALS Functional Rating Scale-Revised Swallow (ALSFRS-R Sw)], using Spearman’s correlation coefficients. Responsiveness was determined with the standardized response mean (SRM). For inter- and intrarater reliabilities, the weighted kappas were 0.95 and 1.00, respectively, for DMD; and 0.98 and 0.98, respectively, for ALS. The NdSSS showed strong correlations with the FOIS (rs = 0.87 for DMD, rs = 0.93 for ALS, p < 0.001), FILS (rs = 0.89 for DMD, rs = 0.92 for ALS, p < 0.001), and ALSFRS-R SW (rs = 0.93, p < 0.001). SRMs were 0.65 for DMD and 1.21 for ALS. The SRM was higher in DMD patients for the NdSSS than for the other scales, while it was similar in ALS patients and the other scales. Our originally developed NdSSS demonstrated sufficient reliability, validity, and responsiveness in patients with DMD and ALS. It is also useful in evaluating dysphagia in patients with progressive neuromuscular diseases.
Literatur
1.
Zurück zum Zitat Greenwood DI (2013) Nutrition management of amyotrophic lateral sclerosis. Nutr Clin Pract 28:392–399CrossRefPubMed Greenwood DI (2013) Nutrition management of amyotrophic lateral sclerosis. Nutr Clin Pract 28:392–399CrossRefPubMed
2.
Zurück zum Zitat Martigne L, Seguy D, Pellegrini N, Orlikowski D, Cuisset JM, Carpentier A, Tiffreau V, Guimber D, Gottrand F (2010) Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr 29:60–64CrossRefPubMed Martigne L, Seguy D, Pellegrini N, Orlikowski D, Cuisset JM, Carpentier A, Tiffreau V, Guimber D, Gottrand F (2010) Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr 29:60–64CrossRefPubMed
3.
Zurück zum Zitat Higo R, Tayama N, Nito T (2004) Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis. Auris Nasus Larynx 31:247–254CrossRefPubMed Higo R, Tayama N, Nito T (2004) Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis. Auris Nasus Larynx 31:247–254CrossRefPubMed
4.
Zurück zum Zitat Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13–21CrossRefPubMed Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13–21CrossRefPubMed
5.
Zurück zum Zitat Crary MA, Mann GD, Groher ME (2005) Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil 86:1516–1520CrossRefPubMed Crary MA, Mann GD, Groher ME (2005) Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil 86:1516–1520CrossRefPubMed
6.
Zurück zum Zitat Kunieda K, Ohno T, Fujishima I, Hojo K, Morita T (2013) Reliability and validity of a tool to measure the severity of dysphagia: the Food Intake LEVEL Scale. J Pain Symptom Manage 46:201–206CrossRefPubMed Kunieda K, Ohno T, Fujishima I, Hojo K, Morita T (2013) Reliability and validity of a tool to measure the severity of dysphagia: the Food Intake LEVEL Scale. J Pain Symptom Manage 46:201–206CrossRefPubMed
7.
Zurück zum Zitat Swinyard CA, Deaver GG, Greenspan L (1957) Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases. Arch Phys Med Rehabil 38:574–579PubMed Swinyard CA, Deaver GG, Greenspan L (1957) Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases. Arch Phys Med Rehabil 38:574–579PubMed
8.
Zurück zum Zitat Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL (1996) A Penetration-Aspiration Scale. Dysphagia 11:93–98CrossRefPubMed Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL (1996) A Penetration-Aspiration Scale. Dysphagia 11:93–98CrossRefPubMed
9.
Zurück zum Zitat Han TR, Paik NJ, Park JW, Kwon BS (2008) The prediction of persistent dysphagia beyond six months after stroke. Dysphagia 23:59–64CrossRefPubMed Han TR, Paik NJ, Park JW, Kwon BS (2008) The prediction of persistent dysphagia beyond six months after stroke. Dysphagia 23:59–64CrossRefPubMed
10.
Zurück zum Zitat Kim J, Oh BM, Kim JY, Lee GJ, Lee SA, Han TR (2014) Validation of the videofluoroscopic dysphagia scale in various etiologies. Dysphagia 29:438–443CrossRefPubMed Kim J, Oh BM, Kim JY, Lee GJ, Lee SA, Han TR (2014) Validation of the videofluoroscopic dysphagia scale in various etiologies. Dysphagia 29:438–443CrossRefPubMed
11.
Zurück zum Zitat Garratt AM, Ruta DA, Abdalla MI, Russell IT (1994) SF 36 health survey questionnaire: II. Responsiveness to changes in health status in four common clinical conditions. Qual Health Care 3:186–192PubMedCentralCrossRefPubMed Garratt AM, Ruta DA, Abdalla MI, Russell IT (1994) SF 36 health survey questionnaire: II. Responsiveness to changes in health status in four common clinical conditions. Qual Health Care 3:186–192PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Liang MH, Fossel AH, Larson MG (1990) Comparisons of five health status instruments for orthopedic evaluation. Med Care 28:632–642CrossRefPubMed Liang MH, Fossel AH, Larson MG (1990) Comparisons of five health status instruments for orthopedic evaluation. Med Care 28:632–642CrossRefPubMed
13.
Zurück zum Zitat Aloysius A, Born P, Kinali M, Davis T, Pane M, Mercuri E (2008) Swallowing difficulties in Duchenne muscular dystrophy: indications for feeding assessment and outcome of videofluroscopic swallow studies. Eur J Paediatr Neurol 12:239–245CrossRefPubMed Aloysius A, Born P, Kinali M, Davis T, Pane M, Mercuri E (2008) Swallowing difficulties in Duchenne muscular dystrophy: indications for feeding assessment and outcome of videofluroscopic swallow studies. Eur J Paediatr Neurol 12:239–245CrossRefPubMed
14.
Zurück zum Zitat Briani C, Marcon M, Ermani M, Costantini M, Bottin R, Iurilli V, Zaninotto G, Primon D, Feltrin G, Angelini C (1998) Radiological evidence of subclinical dysphagia in motor neuron disease. J Neurol 245:211–216CrossRefPubMed Briani C, Marcon M, Ermani M, Costantini M, Bottin R, Iurilli V, Zaninotto G, Primon D, Feltrin G, Angelini C (1998) Radiological evidence of subclinical dysphagia in motor neuron disease. J Neurol 245:211–216CrossRefPubMed
15.
Zurück zum Zitat Shinonaga C, Fukuda M, Suzuki Y, Higaki T, Ishida Y, Ishii E, Hyodo M, Morimoto T, Sano N (2008) Evaluation of swallowing function in Duchenne muscular dystrophy. Dev Med Child Neurol 50:478–480CrossRefPubMed Shinonaga C, Fukuda M, Suzuki Y, Higaki T, Ishida Y, Ishii E, Hyodo M, Morimoto T, Sano N (2008) Evaluation of swallowing function in Duchenne muscular dystrophy. Dev Med Child Neurol 50:478–480CrossRefPubMed
16.
Zurück zum Zitat Jaffe KM, McDonald CM, Ingman E, Haas J (1990) Symptoms of upper gastrointestinal dysfunction in Duchenne muscular dystrophy: case-control study. Arch Phys Med Rehabil 71:742–744PubMed Jaffe KM, McDonald CM, Ingman E, Haas J (1990) Symptoms of upper gastrointestinal dysfunction in Duchenne muscular dystrophy: case-control study. Arch Phys Med Rehabil 71:742–744PubMed
Metadaten
Titel
Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS)
verfasst von
Ayako Wada
Michiyuki Kawakami
Meigen Liu
Eri Otaka
Atsuko Nishimura
Fumio Liu
Tomoyoshi Otsuka
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 10/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7836-y

Weitere Artikel der Ausgabe 10/2015

Journal of Neurology 10/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.